Capmatinib

SKU: orb1306960

Description

Capmatinib (INCB28060) is a selective, orally administered c-MET (HGFR) tyrosine kinase inhibitor. It is widely used in preclinical research, including in vitro cell-based assays and in vivo xenograft models, to investigate targeted therapies for cancers with MET dysregulation, such as non-small cell lung cancer.

Research Area

Cell Biology, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 1029712-80-8
• MW: 412.42
• Purity: 99.76% (May vary between batches)
• Formula: C₂₃H₁₇FN₆O
• SMILES: CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1
• Target: c-Met/HGFR|||Apoptosis
• Solubility: DMSO:4.13 mg/mL (10.01 mM)

Bioactivity

• Target IC50:
  c-Met:0.13 nM
• In Vivo:
  In tumor cells, INCB28060 inhibits cell proliferation and survival by downregulating c-MET phosphorylation and the signaling pathways mediated by c-MET.
  Read more...
• In Vitro:
  In a c-MET-dependent mouse tumor model, the oral administration of INCB28060 (0.03 mg/kg) effectively inhibited tumor growth.
• Cell Research:
  H441 cells are seeded in RPMI-1640 medium containing 10% FBS and grown to complete confluence. Gaps are introduced by scraping cells with a P200 pipette tip. Cells are then stimulated with 50 ng/mL recombinant human HGF to induce migration across the gap in the presence of various concentrations of INCB28060. After an overnight incubation, representative photographs are taken and a semiqualitative assessment of inhibition of cell migration is conducted.(Only for Reference)
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

U-87MG, orally active, SNU-5, S114, c-Met/HGFR, cMet/HGFR, c-Met, cMet, Capmatinib, Balb/c nu/nu mice, ATP competitive, Apoptosis, NVP-INC 280, NVP-INC280, NVP-INC-280, inhibit, INC 280, INC280, INC-280, INCB 28060, INCB28060, INCB-28060, HGFR, Inhibitor, H441

Compound Identifiers

PubChem CID

25145656